SG11202109850SA - Non-viral dna vectors and uses thereof for expressing fviii therapeutics - Google Patents
Non-viral dna vectors and uses thereof for expressing fviii therapeuticsInfo
- Publication number
- SG11202109850SA SG11202109850SA SG11202109850SA SG11202109850SA SG 11202109850S A SG11202109850S A SG 11202109850SA SG 11202109850S A SG11202109850S A SG 11202109850SA SG 11202109850S A SG11202109850S A SG 11202109850SA
- Authority
- SG
- Singapore
- Prior art keywords
- viral dna
- dna vectors
- expressing fviii
- therapeutics
- fviii therapeutics
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2820/00—Vectors comprising a special origin of replication system
- C12N2820/60—Vectors comprising a special origin of replication system from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962817904P | 2019-03-13 | 2019-03-13 | |
US201962856432P | 2019-06-03 | 2019-06-03 | |
PCT/US2020/022738 WO2020186207A2 (en) | 2019-03-13 | 2020-03-13 | Non-viral dna vectors and uses thereof for expressing fviii therapeutics |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202109850SA true SG11202109850SA (en) | 2021-10-28 |
Family
ID=72426821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202109850S SG11202109850SA (en) | 2019-03-13 | 2020-03-13 | Non-viral dna vectors and uses thereof for expressing fviii therapeutics |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220177545A1 (en) |
EP (1) | EP3938523A4 (en) |
JP (1) | JP2022524434A (en) |
KR (1) | KR20210151785A (en) |
CN (1) | CN113874513A (en) |
AU (1) | AU2020234713A1 (en) |
BR (1) | BR112021017853A2 (en) |
CA (1) | CA3133255A1 (en) |
IL (1) | IL286284A (en) |
MA (1) | MA55313A (en) |
MX (1) | MX2021011039A (en) |
SG (1) | SG11202109850SA (en) |
WO (1) | WO2020186207A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL299925A (en) | 2020-07-27 | 2023-03-01 | Anjarium Biosciences Ag | Compositions of dna molecules, methods of making therefor, and methods of use thereof |
WO2023135273A2 (en) * | 2022-01-14 | 2023-07-20 | Anjarium Biosciences Ag | Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2220222A4 (en) * | 2007-11-19 | 2011-10-12 | Univ California | Novel assay for inhibitors of egfr |
US20120263743A1 (en) * | 2009-04-30 | 2012-10-18 | Cytos Biotechnology Ag | Influenza hemagglutinin compositions and uses thereof |
LT3889173T (en) * | 2013-02-15 | 2023-10-10 | Bioverativ Therapeutics Inc. | Optimized factor viii gene |
HUE050484T2 (en) * | 2013-09-12 | 2020-12-28 | Biomarin Pharm Inc | Aav vectors comprising a gene encoding factor viii |
GB2526339A (en) * | 2014-05-21 | 2015-11-25 | Imp Innovations Ltd | Lentiviral vectors |
KR20180034467A (en) * | 2015-08-03 | 2018-04-04 | 마이오도파 리미티드 | Systemic synthesis and regulation of l-dopa |
MX2018005272A (en) * | 2015-10-28 | 2018-09-18 | Sangamo Therapeutics Inc | Liver-specific constructs, factor viii expression cassettes and methods of use thereof. |
PE20231949A1 (en) * | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTS OF FACTOR VIII REDUCED WITH CpG, COMPOSITIONS AND METHODS AND USES FOR THE TREATMENT OF HEMOSTASY DISORDERS |
AU2017228413A1 (en) * | 2016-03-03 | 2018-08-23 | University Of Massachusetts | Closed-ended linear duplex DNA for non-viral gene transfer |
RU2762257C2 (en) * | 2016-04-15 | 2021-12-17 | Зе Трастис Оф Зе Юниверсити Оф Пенсильвания | Gene therapy for the treatment of hemophilia a |
WO2019028192A1 (en) * | 2017-08-01 | 2019-02-07 | Spark Therapeutics, Inc. | Factor viii (fviii) gene therapy methods |
JP7374883B2 (en) * | 2017-08-09 | 2023-11-07 | バイオベラティブ セラピューティクス インコーポレイテッド | Nucleic acid molecules and their uses |
-
2020
- 2020-03-13 SG SG11202109850S patent/SG11202109850SA/en unknown
- 2020-03-13 KR KR1020217029545A patent/KR20210151785A/en active Search and Examination
- 2020-03-13 AU AU2020234713A patent/AU2020234713A1/en active Pending
- 2020-03-13 JP JP2021554696A patent/JP2022524434A/en active Pending
- 2020-03-13 EP EP20769344.1A patent/EP3938523A4/en active Pending
- 2020-03-13 WO PCT/US2020/022738 patent/WO2020186207A2/en unknown
- 2020-03-13 BR BR112021017853A patent/BR112021017853A2/en unknown
- 2020-03-13 CA CA3133255A patent/CA3133255A1/en active Pending
- 2020-03-13 MA MA055313A patent/MA55313A/en unknown
- 2020-03-13 US US17/437,123 patent/US20220177545A1/en active Pending
- 2020-03-13 CN CN202080036209.7A patent/CN113874513A/en active Pending
- 2020-03-13 MX MX2021011039A patent/MX2021011039A/en unknown
-
2021
- 2021-09-12 IL IL286284A patent/IL286284A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN113874513A (en) | 2021-12-31 |
BR112021017853A2 (en) | 2021-11-30 |
WO2020186207A8 (en) | 2020-11-12 |
JP2022524434A (en) | 2022-05-02 |
AU2020234713A1 (en) | 2021-11-04 |
MA55313A (en) | 2022-01-19 |
WO2020186207A3 (en) | 2020-12-17 |
KR20210151785A (en) | 2021-12-14 |
MX2021011039A (en) | 2021-12-15 |
US20220177545A1 (en) | 2022-06-09 |
EP3938523A4 (en) | 2023-06-21 |
EP3938523A2 (en) | 2022-01-19 |
CA3133255A1 (en) | 2020-09-17 |
WO2020186207A2 (en) | 2020-09-17 |
IL286284A (en) | 2021-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1250021A1 (en) | Recombinant promoters and vectors for protein expression in liver and use thereof | |
IL271190A (en) | Enhancing agents for improved cell transfection and/or raav vector production | |
SG10202110491PA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
IL279505A (en) | Chimeric transmembrane proteins and uses thereof | |
IL265489B (en) | Recombinant binding proteins and their use | |
EP3436576A4 (en) | Cell line for recombinant protein and/or viral vector production | |
EP3630987A4 (en) | Recombinant adenoviruses carrying transgenes | |
EP3500112A4 (en) | Brewer's spent-grain based protein powder | |
IL284679A (en) | Multi-functional fusion proteins and uses thereof | |
HK1247111A1 (en) | Polypeptide therapeutics and uses thereof | |
ZA201708638B (en) | Prrsv minor protein¿containing recombinant viral vectors and methods of making and use thereof | |
ZA202101250B (en) | Novel crispr-associated protein and use thereof | |
EP3305802A4 (en) | Novel peptide and composition containing the same | |
IL286283A (en) | Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics | |
IL286284A (en) | Non-viral dna vectors and uses thereof for expressing fviii therapeutics | |
EP3539570A4 (en) | Pegylated endostatin analogue and application thereof | |
SG11202006669RA (en) | Peptides and uses thereof | |
GB2600592B (en) | Polypeptide and use thereof | |
PT3426680T (en) | Activin type 2 receptor binding proteins and uses thereof | |
IL287071A (en) | Factor h vectors and uses thereof | |
ZA201805797B (en) | Novel alpha-1-microglobulin derived proteins and their use | |
EP3947418C0 (en) | Peptides and use thereof | |
EP3445778A4 (en) | Pegylated bioactive peptides and uses thereof | |
IL269751A (en) | Proteins derived from clpb and uses thereof | |
EP3600343A4 (en) | Novel recombinant adeno-associated viral vectors restricting off-target transduction in liver and uses thereof |